Courtesy www.franchiseindia.com
New Delhi: Drug Controller General of India (DCGI) on Friday approved restricted emergency use of Zydus Cadila’s ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infections in adults.
The approval follows promising results from a late-stage study of the drug, and comes in the middle of a massive wave of COVID-19 cases in India, which has overwhelmed its health system and left many hospitals short of critical oxygen supplies.
“A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup,” the company said in a filing.
Bhubaneswar: With cyclonic storm 'Dana' inching towards Odisha, Odisha State Museum, Odisha State Archives and…
Bhubaneswar: The administration in Odisha’s Jagatsinghpur has imposed prohibitory orders under Section 163 of the…
New Delhi: As war rages in different regions of our planet, Prime Minister Narendra Modi…
Bhubaneswar: The Odisha government has removed Chairperson of the State Commission for Women Dr Minati…
Bhubaneswar: The deep depression, which formed over the Bay of Bengal had intensified into a…
Bhubaneswar: The Odisha Cabinet on Wednesday approved certain modifications in the guidelines for the Subhadra…
New Delhi: The Supreme Court on Wednesday pulled up the Central government for rendering the…
Bhubaneswar: Authorised social media handles of Information & Public Relations Dept and Fire Services have…